Clinical Trial Search

Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml

Primary: Change From Baseline to the End-of-treatment Period in the Area Under the Curve of the Rhinitis Total Symptom Score Recorded During 4 Hours (0-4h) of the Allergen…

Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number

Primary: Overall Change From Baseline in TNSS at Visits 3, 4 and 5 — 3.9; 4.1; 5.2 TNSS score (0-12) — p=0.0085

Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score

Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Primary: Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period — 3.18; 3.09; 3.87 Units on a scale (range: 0 to 12) — p=0.0066

Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001

Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants

Primary: The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated. — -1.77; -1.83 units on a…

Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils

Primary: Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in…

Primary: Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment — 4.67; 5.49 Score on a Scale — p=<0.001

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects

Primary: Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008 — 4.4; 4.7 Scores on a scale — p=0.85

Primary: Daily Combined Score (DCS) — -4.41; -1.61 DCS (daily combined score)

Primary: Change From Baseline in D. Farinae HDM-specific IgG4 Antibodies in Serum at 12 Weeks (Part 2) — 0.392; 0.166 Fold Change — p=0.003

Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391

Primary: The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15 — -3.01…

Primary: Area Under the Curve [AUC](Total Score of Symptoms Taking Into Account the Total 5 Symptom Score (T5SS) and Consumption of Rescue Medications (RM) on the Y-axis, and…

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…

Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05

Primary: Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS) During the Primary Efficacy Assessment Period — 3.4; 4.4 score on a scale — p=<0.0001

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale

Primary: Average Total Nasal Symptom Score (TNSS) During Environmental Exposure Chamber (EEC) Challenge Session at Week 24 — 3.83; 5.47; 7.45 Score on a Scale — p=<0.001

Primary: Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at…

Primary: Safety and Tolerability Evaluated on Treatment Emergent Adverse Events — 4; 6; 9; 4 participants

Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units

Primary: Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment — 5; 4; NA Days

Primary: Percentage of Participants Who Experienced At Least One Adverse Event (AE) — 56.9; 53.8; 43.1 Percentage of participants